Methyltestosterone Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Hypogonadism - Male

10 to 50 mg orally once a day.
-or-
5 to 25 mg buccal tablet once a day. Buccal administration allows direct absorption of methyltestosterone into the systemic venous system resulting in delivery of unmetabolized drug to the target tissue. Potency of buccal tablets is 2 times that of oral methyltestosterone.

Usual Adult Dose for Breast Cancer-Palliative

50 to 200 mg orally per day in divided doses.
-or-
25 to 100 mg buccal tablet per day. Buccal administration allows direct absorption of methyltestosterone into the systemic venous system resulting in delivery of unmetabolized drug to the target tissue. Potency of buccal tablets is 2 times that of oral methyltestosterone.

Methyltestosterone is approved by the FDA for the palliation of androgen-responsive metastatic breast cancer in women who are 1 to 5 years postmenopausal or who are proven to have a hormone-dependent tumor noted by previous beneficial response to castration.

Female patients should be observed for signs of virilization. Women should be instructed to report any hoarseness, acne, changes in menstrual periods, or increase in facial hair. Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. A decision may be made by the patient and the physician that some virilization will be tolerated during the treatment for malignant disease.

Usual Adult Dose for Postpartum Breast Pain

80 mg orally per day for 3 to 5 days.

Usual Pediatric Dose for Delayed Puberty - Male

10 to 50 mg orally once a day.
-or-
5 to 25 mg buccal tablet once a day. Buccal administration allows direct absorption of methyltestosterone into the systemic venous system resulting in delivery of unmetabolized drug to the target tissue. Potency of buccal tablets is 2 times that of oral methyltestosterone.

Dosages used to treat delayed puberty are generally started at the lower end of the dosing range and titrated according to patient response and tolerance. The duration of therapy should be limited to 4 to 6 months.

Wrist and hand bone age should be assessed prior to initiation of methyltestosterone therapy and every 6 months to monitor bone maturation. Exogenous androgen therapy can accelerate bone maturation without producing a compensatory gain in linear growth. Use over long periods can result in fusion of the epiphyseal growth centers and termination of the growth process.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

Hide
(web5)